USANA Health Sciences Q1 Revenue Flat, Profit Drops; Reaffirms FY26 Guidance
USNA sits 16% above its 52-week low of $16.6.
Summary
USANA Health Sciences reported flat Q1 revenue of $250 million, which beat analyst estimates, but net profit dropped to $7.50 million, with adjusted EPS falling 16% year-over-year to $0.61. This performance follows a challenging 2025, where the company experienced a significant 74.4% decrease in net earnings. Despite the Q1 profit decline, the company reaffirmed its full-year 2026 guidance for sales, net earnings, and adjusted diluted EPS, suggesting management anticipates a stronger performance later in the year. Positive drivers included growth in China and triple-digit growth from Rise Wellness, which helped offset a 17% decline in Hiya active monthly subscribers. Traders will closely watch if USANA can achieve its reaffirmed guidance and reverse the profit decline in upcoming quarters, especially given the mixed operational results.
At the time of this announcement, USNA was trading at $19.26 on NYSE in the Trade & Services sector, with a market capitalization of approximately $355.5M. The 52-week trading range was $16.60 to $38.32. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.